Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB0805 : Ba/F3  update : 2020/09/24
CommentIL-3 dependent pro B cell line. Conditioned medium. Information.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, a prior written permission of the DEPOSITOR or the RIKEN BRC is necessary.
Remarks
Order Form Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC(cellbank.brc@riken.jp) regarding any kind of for-profit use.
Basic information Depositor Todokoro, Kazuo
Year of deposit 1992
Animal mouse < Mammals
Strain name C3H
Tissue bone marrow
Classification other
Memo_1 Mycoplasma was eliminated with MC-210.
Lifespan infinite
Morphology lymphocyte-like
deposit info
lot info
Medium Medium List
Culture type Suspension cells
Medium and additives RPMI1640 + 10% FBS + 10% (RCB0035 WEHI-3 conditioned medium)
Antibiotics Free
Passage method dilution
Culture information Passage ratio 1 : 10 split
SC frequency Subculture : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
SSLP(mouse) OK
Isozyme LD, NP
Images
deposit info
lot info
Reference information Reference 3
User's Publication 71


To topTop
Reference
4829  Daley GQ1, Baltimore D.  Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein.  Proc Natl Acad Sci U S A  1988  85(23):9312-6  PubMed ID: 3143116
4828  Palacios R, Steinmetz M.  Il-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo.  Cell  1985  41(3):727-34  PubMed ID: 3924409
4827  Palacios R, Henson G, Steinmetz M, McKearn JP.  Interleukin-3 supports growth of mouse pre-B-cell clones in vitro.  Nature  1984  309(5964):126-31  PubMed ID: 6201749

To topTop
User's Publication
12115  Hirai N, Sasaki T, Okumura S, Minami Y, Chiba S, Ohsaki Y.  Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers.  Front Oncol  2020    PubMed ID: 32300555
12148  David Koschut, Debleena Ray, Zhenhua Li, Emanuela Giarin, Jürgen Groet, , Ivan Alić, Shirley Kow-Yin Kham, , Wee Joo Chng, Hany Ariffin, , David M. Weinstock, , Allen Eng-Juh Yeoh, , Giuseppe Basso, , Dean Nižetić  RAS activation via CRLF2 signaling is a widespread mechanism in Down syndrome acute lymphoblastic leukemia regardless of RAS mutations  bioRxiv  2020   
11428  Kang JH, Miettinen TP, Chen L, Olcum S, Katsikis G, Doyle PS, Manalis SR.  Noninvasive monitoring of single-cell mechanics by acoustic scattering.  Nat. Methods  2019    PubMed ID: 30742041
4862  Yonesaka K, Kobayashi Y, Hayashi H1, Chiba Y, Mitsudomi T, Nakagawa K.  Dual blockade of EGFR tyrosine kinase using osimertinib and afatinib eradicates EGFR‑mutant Ba/F3 cells.  Oncol Rep  2019  1(2):1059-1066  PubMed ID: 30483795
4865  Eguchi A, Nakakido M, Nagatoishi S, Kuroda D, Tsumoto K, Nagamune T, Kawahara M.  An epitope-directed antibody affinity maturation system utilizing mammalian cell survival as readout.  Biotechnol Bioeng  2019  116(7):1742-1751  PubMed ID: 30883677
4870  Udagawa H#1, Hasako S#2, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi S.  TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.  Mol Cancer Res  2019  17(11):2233-2243  PubMed ID: 31467113
4872  Tanaka H, Sakagami H, Kaneko N, Konagai S, Yamamoto H, Matsuya T, Yuri M, Yamanaka Y, Mori M, Takeuchi M, Koshio H, Hirano M, Kuromitsu S.  Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.  Mol Cancer Ther  2019  18(8):1366-1373  PubMed ID: 31092564
4875  Yuki Uchiharaa, Tomoyuk iOhe, Tadahiko Mashino, Takayuki Kidokoro, Kenji Tago, Hiroomi Tamura, Megumi Funakoshi-Tago  N-Acetyl cysteine prevents activities of STAT3 inhibitors, Stattic and BP-1-102 independently of its antioxidant properties  Pharmacol Rep  2019  71(6):1067-1078  PubMed ID: 31627175
11561  Yamada R, Fukumoto R, Noyama C, Fujisawa A, Oka S, Imamura T.  An epidermis-permeable dipeptide is a potential cosmetic ingredient with partial agonist/antagonist activity toward fibroblast growth factor receptors.  J Cosmet Dermatol  2019  19(2):477-484  PubMed ID: 31099492
11622  Fujino T, Kobayashi Y, Suda K, Koga T, Nishino M, Ohara S, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T.  Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.  J Thorac Oncol  2019  14(10):1753-1765  PubMed ID: 31279006
6896  Kim HJ, Kim HJ, Kim MK, Bae MK, Sung HY, Ahn JH, Kim YH, Kim SC, Ju W.  SPSB1 enhances ovarian cancer cell survival by destabilizing p21.  Biochem Biophys Res Commun  2019  510(3):364-369  PubMed ID: 30712944
10032  Oyama S, Kitamura H, Kuramochi T, Higuchi Y, Matsushita H, Suzuki T, Goto M, Adachi H, Kasutani K, Sakamoto A, Iwayanagi Y, Kaneko A, Nanami M, Fujii E, Esaki K, Takashima Y, Shimaoka S, Hattori K, Kawabe Y.  Cynomolgus monkey model of interleukin-31-induced scratching depicts blockade of human interleukin-31 receptor A by a humanized monoclonal antibody.  Exp. Dermatol.  2018  27:14-21  PubMed ID: 27714851
4160  Koga T, Kobayashi Y, Tomizawa K, Suda K, Kosaka T, Sesumi Y, Fujino T, Nishino M, Ohara S, Chiba M, Shimoji M, Takemoto T, Suzuki M, Jänne PA, Mitsudomi T.  Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.  Lung Cancer  2018    PubMed ID: 30527195
4161  Kobayashi Y, Fujino T, Nishino M, Koga T, Chiba M, Sesumi Y, Ohara S, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T.  EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib.  J Thorac Oncol  2018    PubMed ID: 29410323
4162  Uchihara Y, Tago K, Taguchi H, Narukawa Y, Kiuchi F, Tamura H, Funakoshi-Tago M.  Taxodione induces apoptosis in BCR-ABL-positive cells through ROS generation.  Biochem. Pharmacol.  2018    PubMed ID: 29859988
4163  Funahashi SI, Kawai S, Fujii E, Taniguchi K, Nakano K, Ishikawa S, Aburatani H, Suzuki M.  Generation of an anti-desmoglein 3 antibody without pathogenic activity of pemphigus vulgaris for therapeutic application to squamous cell carcinoma.  J. Biochem.  2018    PubMed ID: 30239818
4164  Yoshida H, Yamada H, Nogami W, Dohi K, Kurino-Yamada T, Sugiyama K, Takahashi K, Gahara Y, Kitaura M, Hasegawa M, Oshima I, Kuwabara K.  Development of a new knock-in mouse model and evaluation of pharmacological activities of lusutrombopag, a novel, nonpeptidyl small-molecule agonist of the human thrombopoietin receptor c-Mpl.  Exp. Hematol.  2018    PubMed ID: 29274361
4269  Hirao T, Yamaguchi M, Kikuya M, Chibana H, Ito K, Aoki S.  Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.  Cancer Sci.  2018    PubMed ID: 29121435
4471  Katayama K, Noguchi K, Sugimoto Y.  Heat shock protein 90 inhibitors overcome the resistance to Fms-like tyrosine kinase 3 inhibitors in acute myeloid leukemia.  Oncotarget  2018  9(76):34240-34258  PubMed ID: 30344940
10205  Nguyen TD, Takasuka H, Kaku Y, Inoue S, Nagamune T, Kawahara M.  Engineering a growth sensor to select intracellular antibodies in the cytosol of mammalian cells.  J. Biosci. Bioeng.  2017  124:125-132  PubMed ID: 28319021
10264  Nagata N, Iwanari H, Kumagai H, Kusano-Arai O, Ikeda Y, Aritake K, Hamakubo T, Urade Y.  Generation and characterization of an antagonistic monoclonal antibody against an extracellular domain of mouse DP2 (CRTH2/GPR44) receptors for prostaglandin D2.  PLoS ONE  2017  12:e0175452  PubMed ID: 28394950
10272  Chiba M, Togashi Y, Bannno E, Kobayashi Y, Nakamura Y, Hayashi H, Terashima M, De Velasco MA, Sakai K, Fujita Y, Mitsudomi T, Nishio K.  Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A.  BMC Cancer  2017  17:281  PubMed ID: 28424065
4570  Funahashi SI, Suzuki Y, Nakano K, Kawai S, Suzuki M.  Generation and characterization of monoclonal antibodies against human LGR6.  J Biochem  2017  161(4):361-368  PubMed ID: 28013222
4842  Kim SY, Ahn T, Bang H, Ham JS, Kim J, Kim ST, Jang J, Shim M, Kang SY, Park SH, Min BH, Lee H, Kang WK, Kim KM, Park W, Lee J.  Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.  Oncotarget  2017  8(9):15014-15022  PubMed ID: 28122360
4859  Cho J, Kim SY, Kim YJ, Sim MH, Kim ST, Kim NKD, Kim K, Park W, Kim JH, Jang KT, Lee J.  Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.  Clin Transl Oncol  2017  19(10):1247-1252  PubMed ID: 28421416
4873  Watanabe M, Nakano K, Kadin ME, Higashihara M, Watanabe T, Horie R.  CD30 Induces Heat Shock Protein 90 and Signal Integration in Classic Hodgkin Lymphoma Cells.  Am J Pathol  2017  187(1):163-175  PubMed ID: 27870927
4878  Uchihara Y, Ueda F, Tago K, Nakazawa Y, Ohe T, Mashino T, Yokota S, Kasahara T, Tamura H, Funakoshi-Tago M.  Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.  PLoS One  2017  12(8):e0183003  PubMed ID: 28806414
4852  Miura T, Nagamune T, Kawahara M.  Ligand-inducible dimeric antibody for selecting antibodies against a membrane protein based on mammalian cell proliferation.  Biotechnol Bioeng  2016  113(5):1113-23  PubMed ID: 26479395
4860  Ishibashi T, Yaguchi A, Terada K, Ueno-Yokohata H, Tomita O, Iijima K, Kobayashi K, Okita H, Fujimura J, Ohki K, Shimizu T, Kiyokawa N.  Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells.  Exp Hematol  2016  44(3):177-88.e5  PubMed ID: 26703895
4867  Ichida Y, Utsunomiya Y, Tomikawa J, Nakabayashi K, Sato T, Onodera M.  Long time-course monitoring of ZFP809-mediated gene silencing in transgene expression driven by promoters containing MLV-derived PBS.  Biosci Biotechnol Biochem  2016  80(1):114-20  PubMed ID: 26252886
4843  Trung LQ, Espinoza JL, An DT, Viet NH1, Shimoda K, Nakao S.  Resveratrol selectively induces apoptosis in malignant cells with the JAK2V617F mutation by inhibiting the JAK2 pathway.  Mol Nutr Food Res  2015  59(11):2143-54  PubMed ID: 26375873
4849  Fujita T, Yuno M, Okuzaki D, Ohki R, Fujii H.  Identification of non-coding RNAs associated with telomeres using a combination of enChIP and RNA sequencing.  PLoS One  2015  10(4):e0123387  PubMed ID: 25874893
4836  Tomita O, Iijima K, Ishibashi T, Osumi T, Kobayashi K, Okita H, Saito M, Mori T, Shimizu T, Kiyokawa N.  Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.  Leuk Res  2014  38(3):361-70  PubMed ID: 24367893
4839  Nakaya Y, Shide K, Naito H, Niwa T, Horio T, Miyake J, Shimoda K.  Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis.  Blood Cancer J  2014  4:e174  PubMed ID: 24413068
4850  Yoshida R1, Kawahara M, Nagamune T.  A novel platform for antibody library selection in mammalian cells based on a growth signalobody.  Biotechnol Bioeng  2014  111(6):1170-9  PubMed ID: 24338724
4851  Yidan Ma, Teruyuki Nagamune, Masahiro Kawahara  Split focal adhesion kinase for probing protein–protein interactions  Biochemical Engineering Journal  2014  90:272-278 
4857  Kawahara M, Hitomi A, Nagamune T.  Antigen-responsive regulation of Cell motility and migration via the signalobodies based on c-Fms and c-Mpl.  Biotechnol Prog  2014  30(2):411-7  PubMed ID: 24375974
4858  Saka K, Kawahara M, Nagamune T.  Quantitative control of intracellular signaling activity through chimeric receptors incorporating multiple identical tyrosine motifs.  Biotechnol Bioeng  2014  111(5):948-55  PubMed ID: 24222636
4866  Kodama T, Tsukaguchi T, Satoh Y, Yoshida M, Watanabe Y, Kondoh O, Sakamoto H.  Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer.  Mol Cancer Ther  2014  13(12):2910-8  PubMed ID: 25349307
4838  Li SQ, Cheuk AT, Shern JF, Song YK, Hurd L, Liao H, Wei JS, Khan J.  Targeting wild-type and mutationally activated FGFR4 in rhabdomyosarcoma with the inhibitor ponatinib (AP24534).  PLoS One  2013  8(10):e76551  PubMed ID: 24124571
4841  Takagi M, Sato M, Piao J, Miyamoto S, Isoda T, Kitagawa M, Honda H, Mizutani S.  ATM-dependent DNA damage-response pathway as a determinant in chronic myelogenous leukemia.  DNA Repair (Amst)  2013  12(7):500-7  PubMed ID: 23694754
4845  Nakabayashi H, Kawahara M, Tanaka K, Nagamune T.  Construction of antibody/insulin receptor chimera for growth induction of mammalian cells.  Cytotechnology  2013  65(6):945-53  PubMed ID: 23615961
4846  Saka K, Kawahara M, Nagamune T.  Reconstitution of a cytokine receptor scaffold utilizing multiple different tyrosine motifs.  Biotechnol Bioeng  2013  110(12):3197-204  PubMed ID: 23775041
4855  Tone Y, Kawahara M, Hayashi J, Nagamune T.  Cell fate conversion by conditionally switching the signal-transducing domain of signalobodies.  Biotechnol Bioeng  2013  110(12):3219-26  PubMed ID: 23794462
4861  Saka K, Kawahara M, Teng J, Otsu M, Nakauchi H, Nagamune T.  Top-down motif engineering of a cytokine receptor for directing ex vivo expansion of hematopoietic stem cells.  J Biotechnol  2013  168(4):659-65  PubMed ID: 24070902
4837  Kaneda M1, Odaka T, Suetake H, Tahara D, Miyadai T.  Teleost IL-6 promotes antibody production through STAT3 signaling via IL-6R and gp130.  Dev Comp Immunol  2012  38(2):224-31  PubMed ID: 22469658
4854  Shindoh N, Yoda A, Yoda Y, Sullivan TJ, Weigert O, Lane AA, Kopp N, Bird L, Rodig SJ, Fox EA, Weinstock DM.  Next-generation cDNA screening for oncogene and resistance phenotypes.  PLoS One  2012  7(11):e49201  PubMed ID: 23145123
4880  Itonaga H, Tsushima H, Hata T, Matsuo E, Imanishi D, Imaizumi Y, Kawaguchi Y, Fukushima T, Doi Y, Mori S, Kamihira S, Tomonaga M, Miyazaki Y.  Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa.  Int J Hematol  2012  95(2):209-13  PubMed ID: 22262141
7791  Nakamura M, Uehara Y, Asada M, Honda E, Nagai N, Kimata K, Suzuki M, Imamura T.  Sulfated glycosaminoglycans are required for specific and sensitive fibroblast growth factor (FGF) 19 signaling via FGF receptor 4 and betaKlotho.  J. Biol. Chem.  2011  286:26418-23  PubMed ID: 21653700
4844  Tsuruyama T, Hiratsuka T, Jin G, Imai Y, Takeuchi H, Maruyama Y, Kanaya K, Ozeki M, Takakuwa T, Haga H, Tamaki K, Nakamura T.  Murine leukemia retrovirus integration induces the formation of transcription factor complexes on palindromic sequences in the signal transducer and activator of transcription factor 5a gene during the development of pre-B lymphomagenesis.  Am J Pathol  2011  178(3):1374-86  PubMed ID: 21356387
4888  Ikezoe T, Takeuchi T, Yang J, Adachi Y, Nishioka C, Furihata M, Koeffler HP, Yokoyama A.  Analysis of Aurora B kinase in non-Hodgkin lymphoma.  Lab Invest  2009  89(12):1364-73  PubMed ID: 19823168
4856  Asada M, Honda E, Imamura T.  Biologically active fibroblast growth factor 1 tagged with various epitopes.  BMC Res Notes  2008  1:42  PubMed ID: 18710495
4876  Takada A, Yoshida S, Kajikawa M, Miyatake Y, Tomaru U, Sakai M, Chiba H, Maenaka K, Kohda D, Fugo K, Kasahara M.  Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D.  J Immunol  2008  180(3):1678-85  PubMed ID: 18209064
2882  Maeda T, Yagasaki F, Ishikawa M, Takahashi N, Bessho M.  Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.  Blood  2005  105(5):2115-23  PubMed ID: 15514005
4879  Nawata R, Yujiri T, Nakamura Y, Ariyoshi K, Takahashi T, Sato Y, Oka Y, Tanizawa Y.  MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappaB activation.  Oncogene  2003  22(49):7774-80  PubMed ID: 14586403
4884  Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T.  Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain.  Oncogene  2002  21(16):2555-63 
2559  Shimizu A, Tada K, Shukunami C, Hiraki Y, Kurokawa T, Magane N, Kurokawa-Seo M  A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells.  J Biol Chem  2001  276:11031-40  PubMed ID: 11134040
4871  Feng R, Kabayama A, Uchida K, Hoshino H, Miwa M.  Cell-free entry of human T-cell leukemia virus type 1 to mouse cells.  Jpn J Cancer Res  2001  92(4):410-6  PubMed ID: 11346463
4877  Miyoshi S, Motohashi T, Nakamura Y, Osawa M, Hiroyama T, Kim DK, Tokumoto Y, Nakauchi H.  A transmembrane trap method for efficient cloning of genes encoding proteins possessing transmembrane domain.  Biochem Biophys Res Commun  2001  289(5):1192-8  PubMed ID: 11741319
4832  Kawasaki K1, Akashi S, Shimazu R, Yoshida T, Miyake K, Nishijima M.  Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol.  J Biol Chem  2000  275(4):2251-4  PubMed ID: 10644670
4840  Tsunekawa B, Wada M, Ikeda M, Banba S, Kamachi H, Tanaka E, Honjo M.  The binding between the stem regions of human growth hormone (GH) receptor compensates for the weaker site 1 binding of 20-kDa human GH (hGH) than that of 22-kDa hGH.  J Biol Chem  2000  275(21):15652-6  PubMed ID: 10748003
4853  Odajima J, Matsumura I, Sonoyama J, Daino H, Kawasaki A, Tanaka H, Inohara N, Kitamura T, Downward J, Nakajima K, Hirano T, Kanakura Y.  Full oncogenic activities of v-Src are mediated by multiple signaling pathways. Ras as an essential mediator for cell survival.  J Biol Chem  2000  275(31):24096-105  PubMed ID: 10918073
3112  Yoneda A, Asada M, Oda Y, Suzuki M, Imamura T.  Engineering of an FGF-proteoglycan fusion protein with heparin-independent, mitogenic activity.  Nat Biotechnol  2000  18(6):641-4  PubMed ID: 10835602
4831  Kume A1, Ito K, Ueda Y, Hasegawa M, Urabe M, Mano H, Ozawa K.  A G-CSF receptor-gyrase B fusion gene: A new type of molecular switch for expansion of genetically modified hematopoietic cells.  Biochem Biophys Res Commun  1999  260(1):9-12  PubMed ID: 10381335
4833  Matsuda KM, Kume A, Ueda Y, Urabe M, Hasegawa M, Ozawa K.  Development of a modified selective amplifier gene for hematopoietic stem cell gene therapy  Gene Ther  1999  6(6):1038-44  PubMed ID: 10455406
4834  Xu R, Kume A, Matsuda KM, Ueda Y, Kodaira H, Ogasawara Y, Urabe M, Kato I, Hasegawa M, Ozawa K.  A selective amplifier gene for tamoxifen-inducible expansion of hematopoietic cells.  J Gene Med  1999  1(4):236-44  PubMed ID: 10738556
4848  Yoneda A, Asada M, Suzuki M, Imamura T.  Introduction of an N-glycosylation cassette into proteins at random sites: expression of neoglycosylated FGF.  Biotechniques  1999  27(3):576-8  PubMed ID: 10489617
2271  Wada M, Uchida H, Ikeda M, Tsunekawa B, Naito N, Banba S, Tanaka E, Hashimoto Y, Honjo M.  The 20-kilodalton (kDa) human growth hormone (hGH) differs from the 22-kDa hGH in the complex formation with cell surface hGH receptor and hGH-binding protein circulating in human plasma.  Mol Endocrinol  1998  2(1):146-56  PubMed ID: 9440818
4830  Sasaki M, Sasaki T, Enami J.  Prolactin-dependent growth and gamma-casein gene expression in Ba/F3 cells transfected with a long form of mouse mammary prolactin receptor.  Endocr J  1996  43(1):45-52  PubMed ID: 8732451
4883  Palaga T, Kataoka T, Woo JT, Nagai K.  Suppression of apoptotic cell death of IL-3-dependent cell lines by ER/SR Ca2+-ATPase inhibitors upon IL-3 deprivation.  Exp Cell Res  1996  228(1):92-7  PubMed ID: 8892975
4835  Miyake K, Yamashita Y, Ogata M, Sudo T, Kimoto M.  RP105, a novel B cell surface molecule implicated in B cell activation, is a member of the leucine-rich repeat protein family.  J Immunol  1995  154(7):3333-40  PubMed ID: 7897216



Back Back Return Top Page